What Oncology Drug Developers Should Expect from the FDA’s Project Optimus
Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This…
CertaraJanuary 13, 2022
PBPK Modeling of Antibody-Drug Conjugates – Concept and Application
Antibody-Drug Conjugates (ADCs) can be an ideal drug treatment for cancer because they deliver a…
CertaraJanuary 13, 2022
When Should I Select an eCTD Vendor for My Regulatory Submission?
As your company moves towards the regulatory submission of a marketing application to a health…
CertaraJanuary 10, 2022
Certara University Express Webinar: Part 2: Introduction to RsNLME and overview of expanded workflow
Certara University Express Webinar: Part 2: Introduction to RsNLME and overview of expanded workflow
Introduction to RsNLME and its capabilities for population PK/PD modeling.
CertaraJanuary 5, 2022
Certara University Express Webinar: Part 1: Introduction to RsNLME (R speaks NLME)
Introduction to RsNLME and its capabilities for population PK/PD modeling.
CertaraJanuary 5, 2022
Certara Acquires Integrated Nonclinical Development Solutions
Expands software portfolio and nonclinical drug development expertise PRINCETON, N.J.— Jan 5, 2022– Certara, Inc.,…
CertaraJanuary 5, 2022
Strategic Application of PBPK Modeling for Predicting DDIs & the Effects of Smoking & Organ Impairment
Olanzapine is a highly effective antipsychotic, but its uses are limited by the risk of…
CertaraDecember 23, 2021
ScienceDirect: Effect of early treatment with metformin on risk of emergency care and hospitalization among patients with COVID-19: The TOGETHER randomized platform clinical trial
Observational studies have postulated a therapeutic role of metformin in treating COVID-19. We conducted ...(cont.)
CertaraDecember 22, 2021
